India, Nov. 20 -- Sun Pharma Advanced Research Company Ltd (SPARC) announced that Ocuvex Therapeutics Inc. has resubmitted the Complete Response Letter (CRL) for the PDP-716 New Drug Application (NDA) to the US FDA.
The resubmission addresses facility inspection-related issues at a third-party API manufacturing site, which were highlighted in the FDA's July 2023 CRL. The agency had not raised any concerns regarding PDP-716's safety or efficacy.
SPARC said it will provide further updates once the FDA confirms the resubmission is complete.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....